Synopsis
The key role of G protein-coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to be holding this 7½th interim meeting in the series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.
The meeting will consist of:
Clinical candidates
Case studies in GPCR drug discovery and development
New structural biology and drug design
Allosteric modulation
Exhibitor sponsor opportunities
Two afternoon sessions
Programme
For the current programme and list of confirmed speakers, please click here.
Programme
Wednesday 24 February
|
|
Session chair:Adrian Hall, UCB, BE
|
13.00
|
Opening remarks
|
13.05
|
The resolution revolution: GPCR structure-based drug design in 2020 vision
James Errey, Evotec, UK
|
13.40
|
Exhibitor talk 1
|
13.45
|
Structurally enabled discovery of orally bioavailable macrocyclic antagonists of the Calcitonin Gene-Related Peptide (CGRP) receptor
Andrew Cansfield, Sosei Heptares, UK
|
14.20
|
Refreshment break
|
|
Session chair:to be confirmed, Evotec, IT
|
14.35
|
Fragment- and structure-guided drug design using ConfoBodies delivers novel, superior chemotypes on difficult to drug GPCRs
Christel Menet, Confo Therapeutics, BE
|
15.10
|
Exhibitor talk 2
|
15.15
|
Discovery of brain penetrant vasopressin 1a receptor antagonists
Hasani Ratni, F Hoffmann-La Roche, CH
|
15.50
|
Open discussion
|
16.15
|
Close
|
|
|
Thursday 25 February
|
|
Session chair:Daniele Andreotti, Evotec, IT
|
13.00
|
Opening remarks
|
13.05
|
Structural changes in GPCRs upon G protein and arrestin coupling
Chris Tate, Laboratory of Molecular Biology, Medical Research Council, UK
|
13.40
|
Exhibitor talk 3
|
13.45
|
Receptor mutations meets ligand SAR: a powerful tool to aid computational modelling
Anneli Nordqvist, AstraZeneca, SE
|
14.20
|
Refreshment break
|
|
Session chair:Caroline Low, Consultant, UK
|
14.35
|
The challenging task of modulating the GABAB receptor: an academic perspective
Claudia Mugnaini, University of Siena, IT
|
15.10
|
Exhibitor talk 4
|
15.15
|
BAY 2395840 – a potent and selective hBradykinin B1 receptor antagonist, generated within the Bayer-Evotec Strategic Alliance
Adam Davenport, Evotec, UK
|
15.50
|
Closing remarks
Caroline Low, Consultant
followed by Open discussion
|
16.15
|
Close
|
|
Fees
Discounted rates will be offered to SCI and RSC student members, and some student bursaries will be available on application. For further details, please click here.
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
Booking terms and conditions
Call for abstract
For more information, please click
here.
Organising committee
- Daniele Andreotti, Evotec, Italy
- Adrian Hall, UCB, Belgium
-
Duncan Hay, Vertex, UK
- Caroline Low, Consultant, UK
- Nigel Swain, Sosei Heptares, UK
Exhibition and Sponsorship
For further details, please click
here.
Contact
Maggi Churchouse
Tel: +44 (0)1359 221004
Email:maggi@maggichurchouseevents.co.uk